Close
Almac
Achema middle east

U.S. Southeast ‘Stroke Belt’ Also Shows Higher Rates of Cognitive Decline

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Aligning Scientific Innovation with Commercial Reality in Drug Development

The "Valley of Death" in pharma is no longer just about scientific failure; it is about commercial irrelevance. This article examines the critical need to align R&D ambition with market reality early in development. It explores the evolution of the Target Product Profile (TPP) into the Target Value Profile (TVP), the role of the "commercial scientist," and strategies for integrated evidence generation that satisfy both regulators and payers.

How Advanced Analytics is Redefining Pharma Project Prioritization

The era of "gut feeling" in pharmaceutical portfolio management is ending. This article explores how advanced analytics, machine learning, and predictive modeling are revolutionizing project prioritization. It details the shift to Monte Carlo simulations, integrated data lakes, and AI-driven decision support, enabling companies to objectively rank programs and optimize R&D return on investment.

Rethinking Pipeline Value Beyond Peak Sales Forecasts

The traditional reliance on risk-adjusted Net Present Value (rNPV) and peak sales forecasts is failing to capture the true potential of modern pharmaceutical assets, particularly platform technologies. This article introduces holistic valuation frameworks like Real Options Analysis (ROA) and the Platform VISTA model, arguing for a shift toward valuing "strategic fit," "lifecycle potential," and the intangible equity of innovation engines.
- Advertisement -

People living in an area of the southeastern United States known as the “Stroke Belt” are also at greater risk for cognitive decline, or reduced brain function, than those living in other areas, new research suggests.

The Stroke Belt states — known to have significantly higher rates of stroke deaths than the rest of the country — include Alabama, Arkansas, Georgia, Louisiana, Mississippi, North Carolina, South Carolina and Tennessee. According to the researchers, shared risk factors for stroke and brain impairment appear to be to blame for the greater incidence of cognitive decline in this geographic region.

The new study, published online May 26 in Annals of Neurology, followed more than 30,000 Americans aged 45 or older for a period of four years to document signs of stroke as well as cognitive decline.
In assessing reduced cognitive function, the researchers included nearly 24,000 participants (38 percent were black, and 62 percent were white) with normal brain function and no history of stroke. More than half of those participating in the study, or 56 percent, were from Stroke Belt states, while 44 percent were from other parts of the country.

After subjecting participants to brain function tests, including memory and perception of time, the researchers found that roughly 8 percent showed cognitive impairment over the course of the study period. In addition, those living in the Stroke Belt states had an 18 percent higher risk of cognitive decline than those living elsewhere in the country.

“Our study is the first to document higher incidence of cognitive impairment in the Stroke Belt compared to remaining U.S. regions,” Virginia Wadley, associate professor of medicine at the University of Alabama at Birmingham, said in a journal news release.

The study’s authors noted that more research is needed to examine other possible risk factors for reduced brain function, including migration patterns, urban versus rural living, socioeconomic status and education.

“Investigating regional patterns that contribute to modifiable risk factors affecting cognitive decline will allow for prevention and intervention efforts that are geographically concentrated,” Wadley concluded.

The study authors also suggested that their findings could help improve treatments and other services for those at greatest risk for cognitive decline.

Latest stories

Related stories

Aligning Scientific Innovation with Commercial Reality in Drug Development

The "Valley of Death" in pharma is no longer just about scientific failure; it is about commercial irrelevance. This article examines the critical need to align R&D ambition with market reality early in development. It explores the evolution of the Target Product Profile (TPP) into the Target Value Profile (TVP), the role of the "commercial scientist," and strategies for integrated evidence generation that satisfy both regulators and payers.

How Advanced Analytics is Redefining Pharma Project Prioritization

The era of "gut feeling" in pharmaceutical portfolio management is ending. This article explores how advanced analytics, machine learning, and predictive modeling are revolutionizing project prioritization. It details the shift to Monte Carlo simulations, integrated data lakes, and AI-driven decision support, enabling companies to objectively rank programs and optimize R&D return on investment.

Rethinking Pipeline Value Beyond Peak Sales Forecasts

The traditional reliance on risk-adjusted Net Present Value (rNPV) and peak sales forecasts is failing to capture the true potential of modern pharmaceutical assets, particularly platform technologies. This article introduces holistic valuation frameworks like Real Options Analysis (ROA) and the Platform VISTA model, arguing for a shift toward valuing "strategic fit," "lifecycle potential," and the intangible equity of innovation engines.

Building Resilient Pharma Portfolios in an Era of Scientific and Market Uncertainty

Pharmaceutical companies are radically redesigning portfolio strategies to survive a "triple threat" environment of scientific complexity, regulatory upheaval like the IRA, and capital scarcity. This analysis explores the shift from efficiency-driven models to resilience-first frameworks, detailing how leaders are embedding optionality into pipelines, embracing modality agnosticism, and using dynamic resource allocation to thrive amidst volatility.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »